Morgan Stanley raised the firm’s price target on Insmed (INSM) to $102 from $90 and keeps an Overweight rating on the shares. Results from the Phase 2b trial evaluating treprostinil palmitil inhalation powder hit a “home run” scenario, showing significant efficacy across primary and secondary endpoints, the analyst tells investors. Following the data, the firm raised its view of the odds of success in pulmonary arterial hypertension to 85% from 55% and is boosting peak sales estimates “significantly.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Mizuho ups Insmed target on ‘grand slam’ PAH data
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment
- Insmed price target raised to $109 from $94 at BofA
- Insmed price target raised to $120 from $90 at H.C. Wainwright
- Insmed price target raised to $119 from $107 at Wells Fargo